Business
5 views

Moderna, Merck Revive mRNA Hopes With Melanoma Success

Moderna, Merck Revive mRNA Hopes With Melanoma Success

A personalized vaccine developed by Moderna and Merck reduced the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer.

Bloomberg Verified Source

Syndicated via official news feed

Explore all Business stories

Syndicated feed content with full publisher credit.

Business Desk

More in Business

Continue reading verified coverage and related developments on this desk.

View All

More from Business

Latest developments and reports from the desk

All stories →